In addition, the combination of buparlisib and a MEK inhibitor trametinib has a synergistic anti-tumor effect, confirming that crosstalk between PI3K/AKT/mTOR and MAPK/MEK/ERK signaling may contribute to PI3K inhibitor resistance [26]. Here, MAP2K7 is linked to neoplasm.